Parvus Therapeutics Overview

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Parvus Therapeutics General Information

Description

Developer of proprietary pMHC nanomedicine drug candidates designed to trigger the in vivo generation of antigen-specific regulatory T cells (Tregs). The company offers novel drug candidates that restore organ-specific immune tolerance, enabling patients with autoimmune diseases to potentially halt and cure their condition while preserving normal immune function.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 256 East Grand Avenue 103
  • South San Francisco, CA 94080
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 256 East Grand Avenue 103
  • South San Francisco, CA 94080
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Parvus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 01-Feb-2026 Completed Clinical Trials - Phase 1
5. Later Stage VC 20-Mar-2024 Completed Clinical Trials - Phase 1
4. Corporate 16-May-2019 Completed Clinical Trials - Phase 1
3. Corporate 19-Apr-2017 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator Completed Startup
1. Grant 30-Jul-2009 $222K Completed Startup
To view Parvus Therapeutics’s complete valuation and funding history, request access »

Parvus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Parvus Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Genentech Corporation Minority
Novartis Corporation Minority
To view Parvus Therapeutics’s complete investors history, request access »

Parvus Therapeutics FAQs

  • Where is Parvus Therapeutics headquartered?

    Parvus Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Parvus Therapeutics?

    Parvus Therapeutics has 22 total employees.

  • What industry is Parvus Therapeutics in?

    Parvus Therapeutics’s primary industry is Drug Discovery.

  • Is Parvus Therapeutics a private or public company?

    Parvus Therapeutics is a Private company.

  • What is Parvus Therapeutics’s current revenue?

    The current revenue for Parvus Therapeutics is .

  • Who are Parvus Therapeutics’s investors?

    AbbVie Ventures, Genentech, and Novartis have invested in Parvus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process